ライフサイエンスコーパス: vasoactive intestinal peptide

1 GM-CSF, and IL-4 as well as the neuropeptide vasoactive intestinal peptide.

2 rtion of the OFQ-IR neurons was positive for vasoactive intestinal peptide.

3 hat bound both PACAP and the related peptide vasoactive intestinal peptide.

4 tistatin and calretinin, cholecystokinin, or vasoactive intestinal peptide.

5 dibutyryl cAMP, cholera toxin, forskolin, or vasoactive intestinal peptide.

6 reted by astroglial cells in the presence of vasoactive intestinal peptide.

7 id delivery and other issues associated with vasoactive intestinal peptide.

8 ncrease cAMP levels, including forskolin and vasoactive intestinal peptide.

9 l peptide antagonist [4-Chloro-D-Phe6, Leu17]vasoactive intestinal peptide.

10 de-2, gastric-inhibitory peptide, and prepro-vasoactive intestinal peptide.

11 MP-generating agonists such as forskolin and vasoactive intestinal peptide.

12 hrine (10 microm each) were ineffective, but vasoactive intestinal peptide (1 microm) and forskolin (

13 hereby these responses may be downregulated: vasoactive intestinal peptide (1 microM) elevates cyclic

14 0(-8) M and 15 x 10(-9) M, respectively, for vasoactive intestinal peptide 28.

15 the hypersecretion of insulin (5 patients), vasoactive intestinal peptide (5 patients), gastrin (2 p

16 are predominantly noncholinergic and contain vasoactive intestinal peptide, a marker of secretomotor

17 Vasoactive intestinal peptide, a neuropeptide regulator

18 and duodenal acidity, and overexpressed the vasoactive intestinal peptide-a myorelaxant factor for t

19 n with cholecystokinin (CCK), carbachol, and vasoactive intestinal peptide all induced Rap1 activatio

20 The circadian synchronizer vasoactive intestinal peptide also stimulates ILC2 cells

21 Treatment with vasoactive intestinal peptide, an anti-inflammatory neur

22 hPAC1-R(S) selectivity for PACAP versus the vasoactive intestinal peptide and also differentiate PAC

23 we found that two Gs-coupled receptors (the vasoactive intestinal peptide and beta-adrenergic recept

24 Under in vitro stimulation with vasoactive intestinal peptide and CD40L, IGIP mRNA expre

25 The DeltaF508 mice overexpressed vasoactive intestinal peptide and had defects in gallbla

26 The neuropeptide vasoactive intestinal peptide and inhibitors of poly(ADP

27 hate and Na nitroprusside), or both kinases (vasoactive intestinal peptide and isoproterenol >1 micro

28 In addition, cAMP analogues as well as vasoactive intestinal peptide and isoproterenol, two neu

29 Vasoactive intestinal peptide and its G protein-coupled

30 Vasoactive intestinal peptide and its G-protein-coupled

31 uced in these neurons after axotomy, such as vasoactive intestinal peptide and pituitary adenylate cy

32 Vasoactive intestinal peptide and related factors may pr

33 In particular, the effects of vasoactive intestinal peptide and secretin on intra-acin

34 etion triggered by SubP was synergistic with vasoactive intestinal peptide and/or forskolin but not w

35 (cAMP) production induced by isoproterenol, vasoactive intestinal peptide, and forskolin were also s

36 rosine kinase, endothelial progenitor cells, vasoactive intestinal peptide, and miRNA in PAH therapeu

37 sion of this isotype, including IL-10, IL-2, vasoactive intestinal peptide, and TGF-beta.

38 by NG-nitro-L-arginine methyl ester and the vasoactive intestinal peptide antagonist [4-Chloro-D-Phe

39 Muscarinic M2 receptors, nitric oxide and vasoactive intestinal peptide are inhibitory and regulat

40 ls did not colocalize with those against the vasoactive intestinal peptide-associated protein PHM27.

41 Secretomotor neurons, which release vasoactive intestinal peptide at their junctions with in

42 Vasoactive intestinal peptide binding to VPAC(2) on CD4

43 reverse transcription-PCR and (125)I-labeled vasoactive intestinal peptide binding, both IK-1 and IK-

44 nsmembrane receptors that includes secretin, vasoactive intestinal peptide, calcitonin, and corticotr

45 n mCry1 expression and its interactions with vasoactive intestinal peptide, cAMP, and PER at the hear

46 beta-subunit of cholera toxin, a marker for vasoactive intestinal peptide-containing secretomotor ne

47 neurons were labeled in parvalbumin-Cre and vasoactive intestinal peptide-Cre mice.

48 g, and stimulation of transcription from the vasoactive intestinal peptide cytokine-responsive elemen

49 bombesin also stimulated JNK activity, while vasoactive intestinal peptide did not.

50 Vasoactive intestinal peptide dose-dependently stimulate

51 as elevated, and the dose-response curve for vasoactive intestinal peptide-elicited cAMP accumulation

52 Cells treated with vasoactive intestinal peptide, epinephrine, and dibutyry

53 n (SS), neuropeptide Y, cholecystokinin, and vasoactive intestinal peptide exhibited clearly detectab

54 rents activates muscarinic receptors on both vasoactive intestinal peptide-expressing (VIP) and parva

55 The relative weight of vasoactive intestinal peptide-expressing (Vip) interneur

56 In addition, vasoactive intestinal peptide-expressing axonal plexuses

57 Recent studies on vasoactive intestinal peptide-expressing inhibitory neur

58 Vasoactive intestinal peptide-expressing interneurons (V

59 Finally, vasoactive intestinal peptide-expressing interneurons pr

60 Optogenetic inhibition of vasoactive intestinal peptide-expressing neurons did not

61 ed controls is correlated with the number of vasoactive intestinal peptide-expressing SCN neurons.

62 equired to stimulate depolarization, whereas vasoactive intestinal peptide failed to evoke any respon

63 ing polypeptide (PACAP), a new member of the vasoactive intestinal peptide family expressed in embryo

64 COS-7 cells and increased ability to induce vasoactive intestinal peptide gene expression in IMR-32

65 Vasoactive intestinal peptide had no effect, and its ant

66 To date, two peptides, cholecystokinin and vasoactive intestinal peptide, have been localized to su

67 ns of adoptively transferred N-alpha-syn and vasoactive intestinal peptide immunocytes or natural Tre

68 emistry revealed colocalization of sst2A and vasoactive intestinal peptide immunoreactivities in ente

69 noreactive for parvalbumin, somatostatin, or vasoactive intestinal peptide) in layer 2/3 of mouse vis

70 ted agonist (isoproterenol (isoprenaline) or vasoactive intestinal peptide) in the presence of HCO3-

71 In contrast, purified vasoactive intestinal peptide induced and natural Tregs

72 in a approximately 1.8-fold increase in the vasoactive intestinal peptide-induced activation of aden

73 We report that vasoactive intestinal peptide inhibits the proliferation

74 tide-ir (CGRP-ir) were virtually absent, but vasoactive intestinal peptide-ir (VIP-ir) nerves were pr

75 that of arginine-vasopressin-IR (AVP-IR) and vasoactive intestinal peptide-IR (VIP-IR), but not with

76 F-IR neurons in submucosal ganglia expressed vasoactive intestinal peptide-IR and were likely to be s

77 otor neurons, and that both nitric oxide and vasoactive intestinal peptide may mediate the inhibitory

78 cal trials, this antiproliferative action of vasoactive intestinal peptide may offer a new and promis

79 nt of the core clock gene period, as well as vasoactive intestinal peptide, melatonin, and the cAMP/M

80 tric oxide, cyclooxygenase-2 metabolites and vasoactive intestinal peptide, might modulate neurovascu

81 a cells as LIF and CNTF, including increased vasoactive intestinal peptide mRNA, STAT3 dimerization,

82 gene-related peptide (CGRP), substance P, or vasoactive intestinal peptide, neuropeptides known to be

83 ides neurotensin, somatostatin, motilin, and vasoactive intestinal peptide occur largely in the stoma

84 8-bromo-cyclic AMP, 8-pCPT-2'-O-Me-cAMP, and vasoactive intestinal peptide on amylase release by 60%

85 d by gp120 was prevented by cotreatment with vasoactive intestinal peptide or activity-dependent neur

86 glands fail to secrete mucus in response to vasoactive intestinal peptide or forskolin; the failure

87 In SCN lacking vasoactive intestinal peptide or its receptor, mCry1 exp

88 rtion of neurons that expressed substance P, vasoactive intestinal peptide or nitric oxide synthase a

89 Endogenous mediators, such as vasoactive intestinal peptide or prostaglandin E2 (PGE2)

90 ation of calcitonin, amylin, neuropeptide Y, vasoactive intestinal peptide, or beta-endorphin.

91 ast, interneurons containing neuropeptide Y, vasoactive intestinal peptide, or the 5-hydroxytryptamin

92 decrease in neuronal nitric oxide synthase, vasoactive intestinal peptide, PACAP, and tyrosine hydro

93 neuron-specific enolase, gastrin, glucagon, vasoactive intestinal peptide, pancreatic polypeptide, a

94 ced increased expression of cholecystokinin, vasoactive intestinal peptide, peptide YY, and somatosta

95 tonin gene-related peptide, substance P, and vasoactive intestinal peptide peptidergic fibers, at two

96 such as MiaPaCa-2 that are negative for the vasoactive intestinal peptide/pituitary adenylate cyclas

97 The vasoactive intestinal peptide/pituitary adenylate cyclas

98 More input to vasoactive intestinal peptide-positive (VIP+) neurons th

99 n-positive, somatostatin-positive (SST+), or vasoactive intestinal peptide-positive (VIP+) neurons, t

100 uted preferentially to surround suppression, vasoactive intestinal peptide-positive interneurons were

101 s primarily signaled motor action (licking), vasoactive intestinal peptide-positive neurons responded

102 nregulation of bone morphogenetic protein 2, vasoactive intestinal peptide, preopro-urotensin II-rela

103 r with three multiple response elements, the vasoactive intestinal peptide promoter and a cAMP respon

104 ADM, CGRP, vasoactive intestinal peptide, prostaglandin E2, isoprot

105 ranscriptional repressor sequence of the rat vasoactive intestinal peptide receptor (VIPR) gene const

106 ografts were analyzed for expression of NTR, vasoactive intestinal peptide receptor (VIPR), substance

107 yndrome, exonic duplications in the gene for vasoactive intestinal peptide receptor 2 (VIPR2), and ex

108 hat, upon agonist stimulation, a GPCR called vasoactive intestinal peptide receptor 2 (VPAC2) is shed

109 Vasoactive intestinal peptide receptor 2 can elicit immu

110 olase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mi

111 located within 89 kilobases upstream of the vasoactive intestinal peptide receptor gene VIPR2.

112 Vasoactive intestinal peptide receptor I (VIPRI) express

113 aneous nerves and mRNA, for the VIP receptor vasoactive intestinal peptide receptor type 1, and vasoa

114 tive intestinal peptide receptor type 1, and vasoactive intestinal peptide receptor type 2 have been

115 tegration of stimulatory (Galpha(s)-mediated vasoactive intestinal peptide receptor) and inhibitory (

116 novel peptide with structural similarity to vasoactive intestinal peptide, regulates production of e

117 Among the vasoactive intestinal peptide/secretin/glucagon family o

118 NF145-IR was found in neurons with vasoactive intestinal peptide, serotonin, nitric oxide s

119 These findings implicate altered vasoactive intestinal peptide signalling in the pathogen

120 cotropin-releasing hormone, neurotensin, and vasoactive intestinal peptide; small molecules include a

121 in number than either the cholecystokinin or vasoactive intestinal peptide subsets, overlapped 100% w

122 tters such as acetylcholine, norepinephrine, vasoactive intestinal peptide, substance P and histamine

123 9.5, neuronal nitric oxide synthase (nNOS), vasoactive intestinal peptide, substance P, and tyrosine

124 based on the tryptase-mediated hydrolysis of vasoactive intestinal peptide that was modified to inclu

125 The strong secretory response to vasoactive intestinal peptide, the acidity of [cAMP](i)-

126 stem cells, we found that costimulation with vasoactive intestinal peptide (V) and phorbol ester (P)

127 onal relationship between cfos expression in vasoactive intestinal peptide (VIP) -containing neurons

128 ylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) activate two shared

129 Conversely, vasoactive intestinal peptide (VIP) activated GIRK chann

130 Vasoactive intestinal peptide (VIP) analog (TP3982) was

131 We find that vasoactive intestinal peptide (VIP) and a VPAC2 (VIP rec

132 ence experiments revealed that antibodies to vasoactive intestinal peptide (VIP) and calbindin-D28K (

133 used to determine the role of G proteins in vasoactive intestinal peptide (VIP) and carbachol-stimul

134 Vasoactive intestinal peptide (VIP) and corticotropin-re

135 Vasoactive intestinal peptide (VIP) and DAPTA (D-ala(1)-

136 e in response to inhibitory neurotransmitter vasoactive intestinal peptide (VIP) and direct electrica

137 spectum, are approximately 50% homologous to vasoactive intestinal peptide (VIP) and glucagon-like pe

138 opic double labeling immunocytochemistry for vasoactive intestinal peptide (VIP) and gonadotrophin-re

139 diated by the primary coupling neuropeptide, vasoactive intestinal peptide (VIP) and its canonical re

140 The vasoactive intestinal peptide (VIP) and its G protein-co

141 Vasoactive intestinal peptide (VIP) and its G protein-co

142 Vasoactive intestinal peptide (VIP) and its G-protein-co

143 (SCG) dramatically increase their content of vasoactive intestinal peptide (VIP) and its mRNA after a

144 Vasoactive intestinal peptide (VIP) and its two G protei

145 HMG) cells were examined for the presence of vasoactive intestinal peptide (VIP) and muscarinic acety

146 The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

147 The effects of vasoactive intestinal peptide (VIP) and pituitary adenyl

148 Neuropeptides such as the vasoactive intestinal peptide (VIP) and pituitary adenyl

149 Vasoactive intestinal peptide (VIP) and pituitary adenyl

150 Neuropeptides such as vasoactive intestinal peptide (VIP) and pituitary adenyl

151 The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

152 The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

153 We reported recently that the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

154 Vasoactive intestinal peptide (VIP) and pituitary adenyl

155 activity in the visual cortex contains both vasoactive intestinal peptide (VIP) and somatostatin (SS

156 o known immunosuppressive neuropeptides, the vasoactive intestinal peptide (VIP) and the pituitary ad

157 The vasoactive intestinal peptide (VIP) and the pituitary ad

158 Vasoactive intestinal peptide (VIP) and the pituitary ad

159 e of two immunomodulatory neuropeptides, the vasoactive intestinal peptide (VIP) and the pituitary ad

160 two structurally related neuropeptides, the vasoactive intestinal peptide (VIP) and the pituitary ad

161 Because the neuropeptide vasoactive intestinal peptide (VIP) and the structurally

162 Vasoactive intestinal peptide (VIP) and the structurally

163 The vasoactive intestinal peptide (VIP) and the structurally

164 Using antibodies directed against vasoactive intestinal peptide (VIP) and tyrosine hydroxy

165 /c mice were injected intraperitoneally with vasoactive intestinal peptide (VIP) antagonist and simil

166 Vasoactive intestinal peptide (VIP) appears to be respon

167 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are implicated in th

168 The major immunoregulatory effects of vasoactive intestinal peptide (VIP) are mediated by stru

169 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are related neuropep

170 Immune cellular effects of vasoactive intestinal peptide (VIP) are transduced by VI

171 is study represents an initial evaluation of vasoactive intestinal peptide (VIP) as a possible regula

172 concentration efficiency for the target drug vasoactive intestinal peptide (VIP) as conventional part

173 s from our laboratory have demonstrated that vasoactive intestinal peptide (VIP) directly converts th

174 Exogenous vasoactive intestinal peptide (VIP) down-regulates pro-i

175 Although vasoactive intestinal peptide (VIP) exerts many of its e

176 In contrast a peptide related to PACAP, vasoactive intestinal peptide (VIP) failed to induce CRE

177 ylate cyclase-activating polypeptide (PACAP)/vasoactive intestinal peptide (VIP) family of peptides m

178 l with muscarinic agonists, substance P, and vasoactive intestinal peptide (VIP) functioning as effec

179 Vasoactive intestinal peptide (VIP) gene expression is h

180 induction of expression of the neuropeptide vasoactive intestinal peptide (VIP) gene is mediated by

181 ceptor subunit activate transcription of the vasoactive intestinal peptide (VIP) gene through a 180 b

182 (TGF-beta) both induce transcription of the vasoactive intestinal peptide (VIP) gene through a 180-b

183 (CNTF) potently induces transcription of the vasoactive intestinal peptide (VIP) gene through a 180-b

184 Vasoactive intestinal peptide (VIP) has a high affinity

185 Vasoactive intestinal peptide (VIP) has a role in immuno

186 The neuropeptide vasoactive intestinal peptide (VIP) has also been found

187 Vasoactive intestinal peptide (VIP) has been found to re

188 The neuropeptide vasoactive intestinal peptide (VIP) has been shown to in

189 Vasoactive intestinal peptide (VIP) has been shown to re

190 Vasoactive intestinal peptide (VIP) has been widely acce

191 Vasoactive intestinal peptide (VIP) has potent antiproli

192 Drosophila is remarkably similar to that of vasoactive intestinal peptide (VIP) in mammals.

193 The prominence of vasoactive intestinal peptide (VIP) in rodent thymic neu

194 a representative type of non-opioid peptides vasoactive intestinal peptide (VIP) in the amygdala to m

195 small proline-rich protein 1a (sprr1a), and vasoactive intestinal peptide (vip) in the trigeminal ga

196 Vasoactive intestinal peptide (VIP) induced REMS respons

197 Vasoactive intestinal peptide (VIP) induces regulatory d

198 Vasoactive intestinal peptide (VIP) induces Th2 response

199 Vasoactive intestinal peptide (VIP) inhibits phasic cont

200 ubpopulations containing parvalbumin (PV) or vasoactive intestinal peptide (VIP) innervate distinct p

201 One solution to this problem could be the vasoactive intestinal peptide (VIP) interneurons, which

202 Vasoactive intestinal peptide (VIP) is a naturally occur

203 Vasoactive intestinal peptide (VIP) is a neuroendocrine

204 Vasoactive intestinal peptide (VIP) is a neurokine that

205 Vasoactive intestinal peptide (VIP) is a neuromediator e

206 Vasoactive intestinal peptide (VIP) is a neuromodulator

207 Vasoactive intestinal peptide (VIP) is a neuropeptide wi

208 Vasoactive intestinal peptide (VIP) is a neurotransmitte

209 Vasoactive intestinal peptide (VIP) is a potent immunomo

210 Vasoactive intestinal peptide (VIP) is an acknowledged n

211 Vasoactive intestinal peptide (VIP) is an anti-inflammat

212 Vasoactive intestinal peptide (VIP) is an anti-inflammat

213 Vasoactive intestinal peptide (VIP) is expressed by corn

214 Vasoactive intestinal peptide (VIP) is more prominent in

215 Vasoactive intestinal peptide (VIP) mediates a broad ran

216 Vasoactive intestinal peptide (VIP) modulates immune res

217 R IR occurs exclusively in 50% of submucosal vasoactive intestinal peptide (VIP) neurons (interneuron

218 ed by sound, while visual responses of L2/L3 vasoactive intestinal peptide (VIP) neurons were suppres

219 n interneurons expressing Cre recombinase in vasoactive intestinal peptide (VIP) or parvalbumin (PV)

220 synthase (NOS), serotonin, substance P (SP), vasoactive intestinal peptide (VIP) or vesicular acetylc

221 To determine whether vasoactive intestinal peptide (VIP) played a role in dev

222 Tryptase cleaves vasoactive intestinal peptide (VIP) producing two major

223 hormone (GHRH) can potentially interact with vasoactive intestinal peptide (VIP) receptors (VPAC(1)-R

224 Breast cancer vasoactive intestinal peptide (VIP) receptors were chara

225 tested the hypothesis that the neuropeptide vasoactive intestinal peptide (VIP) regulates adhesion m

226 Vasoactive intestinal peptide (VIP) released from some n

227 cell line NBFL increased CNTF induction of a vasoactive intestinal peptide (VIP) reporter gene, and i

228 We show that vasoactive intestinal peptide (VIP) secreted by the inne

229 ntaining choline acetyltransferase (ChAT) or vasoactive intestinal peptide (VIP) share characteristic

230 ng parvalbumin (PV), somatostatin (SST), and vasoactive intestinal peptide (VIP) show cell-type-speci

231 demonstrated their dependence upon G-coupled vasoactive intestinal peptide (VIP) signaling.

232 cyclase-activating polypeptide (PACAP), and vasoactive intestinal peptide (VIP) suppress Langerhans

233 Vasoactive intestinal peptide (VIP) suppresses Th1 immun

234 The potent PACAP/vasoactive intestinal peptide (VIP) type I receptor anta

235 decreased the area of nitrergic neurons and vasoactive intestinal peptide (VIP) varicosities.

236 The immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) was cleaved by purif

237 mpartment where the 5-HT4 agonist was added; vasoactive intestinal peptide (VIP) was released only in

238 Vasoactive intestinal peptide (VIP) was shown to be prod

239 s calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) were potent but less

240 rpose of this study was to determine whether vasoactive intestinal peptide (VIP), a 28-amino acid neu

241 Vasoactive intestinal peptide (VIP), a major neurotransm

242 Vasoactive intestinal peptide (VIP), a neuropeptide pres

243 It closely resembles vasoactive intestinal peptide (VIP), a neuropeptide well

244 Vasoactive intestinal peptide (VIP), a neuropeptide with

245 Vasoactive intestinal peptide (VIP), a neuropeptide, may

246 Vasoactive intestinal peptide (VIP), a pulmonary vasodil

247 Vasoactive Intestinal Peptide (VIP), a pulmonary vasodil

248 .5 (PGP 9.5), a general neuronal marker, and vasoactive intestinal peptide (VIP), a sudomotor nerve f

249 cocultured with different concentrations of vasoactive intestinal peptide (VIP), adult rat RPE cells

250 T2) to model HCMV reactivation, we show that vasoactive intestinal peptide (VIP), an immunomodulatory

251 sion of the anti-inflammatory neuropeptides, vasoactive intestinal peptide (VIP), and pituitary adeny

252 G) dramatically increases levels of galanin, vasoactive intestinal peptide (VIP), and substance P and

253 against protein gene product (PGP)-9.5, SP, vasoactive intestinal peptide (VIP), and tyrosine hydrox

254 opulations, expressing somatostatin (SOM) or vasoactive intestinal peptide (VIP), are active as popul

255 es (Abs) to an autoantigen, the neuropeptide vasoactive intestinal peptide (VIP), by a covalently rea

256 ons processed for tyrosine hydroxylase (TH), vasoactive intestinal peptide (VIP), calcitonin gene-rel

257 neuronal markers including parvalbumin (PV), vasoactive intestinal peptide (VIP), calretinin, calbind

258 than 90% of neuronal nitric oxide synthase, vasoactive intestinal peptide (VIP), calretinin, or neur

259 d by silver-gold enhancement of staining for vasoactive intestinal peptide (VIP), cholecystokinin (CC

260 We explored the relation between vasoactive intestinal peptide (VIP), CRTH2, and eosinoph

261 t their regulation by neuropeptides, such as vasoactive intestinal peptide (VIP), during Pseudomonas

262 Vasoactive intestinal peptide (VIP), forskolin, and geni

263 iety of transmitters including nitric oxide, vasoactive intestinal peptide (VIP), gastrin-releasing p

264 essing parvalbumin (PV), somatostatin (SOM), vasoactive intestinal peptide (VIP), or neuropeptide Y.

265 of neuropeptides of the family that includes vasoactive intestinal peptide (VIP), peptide histidine i

266 d by microinjection of a cocktail containing vasoactive intestinal peptide (VIP), peptide histidine i

267 measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate

268 The major 28-aa neuropeptide, vasoactive intestinal peptide (VIP), provides neuroprote

269 ntal Cell, Nedvetsky et al. (2014) find that vasoactive intestinal peptide (VIP), secreted by parasym

270 al that locomotion increases the activity of vasoactive intestinal peptide (VIP), somatostatin (SST)

271 Antibodies to vasoactive intestinal peptide (VIP), tyrosine hydroxylas

272 ne-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), tyrosine hydroxylas

273 ctionally important neuropeptides, including vasoactive intestinal peptide (VIP), which drives light

274 uble-label immunocytochemistry revealed that vasoactive intestinal peptide (VIP)-expressing cells, bu

275 owever, targeting of somatostatin (SOM)- and vasoactive intestinal peptide (VIP)-expressing INs led t

276 tional ErbB4 deletion, we tested the role of vasoactive intestinal peptide (VIP)-expressing interneur

277 to light induces a gene program in cortical vasoactive intestinal peptide (VIP)-expressing neurons t

278 cuit inhibition and a subsequent increase in vasoactive intestinal peptide (VIP)-mediated disinhibiti

279 In contrast, activating vasoactive intestinal peptide (VIP)-positive interneuron

280 g animals revealed that locomotion activates vasoactive intestinal peptide (VIP)-positive neurons in

281 sitive and calretinin (Cr)-positive (but not vasoactive intestinal peptide (VIP)-positive) interneuro

282 inding of (125)I-JV-1-42 is not inhibited by vasoactive intestinal peptide (VIP)-related peptides sha

283 PEG5kDa-cholane) to a 28 amino acid peptide, vasoactive intestinal peptide (VIP).

284 in response to both acetylcholine (ACh) and vasoactive intestinal peptide (VIP).

285 carbon monoxide (CO), nitric oxide (NO), and vasoactive intestinal peptide (VIP).

286 and negative for parvalbumin (PV) as well as vasoactive intestinal peptide (VIP).

287 nd shares two receptors VPAC1 and VPAC2 with vasoactive intestinal peptide (VIP).

288 ctly on nociceptors to induce the release of vasoactive intestinal peptide (VIP).

289 sses from noradrenaline to acetylcholine and vasoactive intestinal peptide (VIP).

290 tion was performed for vasopressin (AVP) and vasoactive intestinal peptide (VIP).

291 litude of pacemaking in SCN circuits lacking vasoactive intestinal peptide (VIP).

292 appaB does not confer MIE gene activation by vasoactive intestinal peptide (VIP).

293 ption, including glucagon-like peptide 1 and vasoactive intestinal peptide (VIP).

294 -Rs) with the selective agonist maxadilan or vasoactive intestinal peptide (VIP)/PACAP (VPAC) recepto

295 originating from the SCN neurons expressing vasoactive intestinal peptide (VIP+ neurons).

296 Epithelial responsiveness to vasoactive intestinal peptide was increased after enteri

297 of parvalbumin (PV), somatostatin (SST), and vasoactive intestinal peptide were decreased in hypoxic-

298 mmunohistochemistry demonstrated that TH and vasoactive intestinal peptide were detectable at P14 and

299 ioactive peptides, angiotensins I and II and vasoactive intestinal peptide, were also hydrolyzed rapi

300 for vesicular acetylcholine transporter and vasoactive intestinal peptide when they reached the ster